Paper39593151
Molecular exploration of natural and synthetic compounds databases for promising hypoxia inducible factor (HIF) Prolyl-4- hydroxylase domain (PHD) inhibitors using molecular simulation and free energy calculations.
Sayaf AM and 8 others. BMC Chem, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Molecular exploration of natural and synthetic compounds databases for promising hypoxia inducible factor (HIF) Prolyl-4- hydroxylase domain (PHD) inhibitors using molecular simulation and free energy calculations. Papers, record 39593151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39593151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Molecular exploration of natural and synthetic compounds databases for promising hypoxia inducible factor (HIF) Prolyl-4- hydroxylase domain (PHD) inhibitors using molecular simulation and free energy calculations.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23721660 | HIM-herbal ingredients in-vivo metabolism database. | J Cheminform | 2013 | https://conductscience.org/library/papers/23721660 | PubMed |
| 2 | 29522307 | Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations. | ACS Chem Neurosci | 2018 | https://conductscience.org/library/papers/29522307 | PubMed |
| 3 | 30682255 | Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway: Development and Therapeutic Applications. | J Med Chem | 2019 | https://conductscience.org/library/papers/30682255 | PubMed |
| 4 | 28928122 | Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia. | J Pharmacol Exp Ther | 2017 | https://conductscience.org/library/papers/28928122 | PubMed |
| 5 | 29532755 | Homocysteine and Hyperhomocysteinaemia. | Curr Med Chem | 2019 | https://conductscience.org/library/papers/29532755 | PubMed |
| 6 | 23937437 | Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. | Annu Rev Pathol | 2014 | https://conductscience.org/library/papers/23937437 | PubMed |
| 7 | 31628888 | Discovery of prolyl hydroxylase 2 inhibitors with new chemical scaffolds as in vivo active erythropoietin inducers through a combined virtual screening strategy. | Chem Biol Drug Des | 2020 | https://conductscience.org/library/papers/31628888 | PubMed |
| 8 | 26610437 | Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications. | Molecules | 2015 | https://conductscience.org/library/papers/26610437 | PubMed |
| 9 | 35498092 | Docking studies and molecular dynamics simulation of triazole benzene sulfonamide derivatives with human carbonic anhydrase IX inhibition activity. | RSC Adv | 2021 | https://conductscience.org/library/papers/35498092 | PubMed |
| 10 | 26656456 | HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. | Nat Rev Nephrol | 2016 | https://conductscience.org/library/papers/26656456 | PubMed |
| 11 | 30849371 | VEGF in Signaling and Disease: Beyond Discovery and Development. | Cell | 2019 | https://conductscience.org/library/papers/30849371 | PubMed |
| 12 | 16200636 | The Amber biomolecular simulation programs. | J Comput Chem | 2005 | https://conductscience.org/library/papers/16200636 | PubMed |
| 13 | 35926869 | Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia. | J Pharmacol Exp Ther | 2022 | https://conductscience.org/library/papers/35926869 | PubMed |
| 14 | 33431011 | Review on natural products databases: where to find data in 2020. | J Cheminform | 2020 | https://conductscience.org/library/papers/33431011 | PubMed |
| 15 | 24205103 | AfroDb: a select highly potent and diverse natural product library from African medicinal plants. | PLoS One | 2013 | https://conductscience.org/library/papers/24205103 | PubMed |
| 16 | 36450832 | Structural analysis of the 2-oxoglutarate binding site of the circadian rhythm linked oxygenase JMJD5. | Sci Rep | 2022 | https://conductscience.org/library/papers/36450832 | PubMed |
| 17 | 24575966 | Predictive in silico off-target profiling in drug discovery. | Future Med Chem | 2014 | https://conductscience.org/library/papers/24575966 | PubMed |
| 18 | 35865575 | Design and synthesis of hybrid compounds as novel drugs and medicines. | RSC Adv | 2022 | https://conductscience.org/library/papers/35865575 | PubMed |
| 19 | 21372172 | Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor. | Mol Pharmacol | 2011 | https://conductscience.org/library/papers/21372172 | PubMed |
| 20 | 21905107 | The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. | Proteins | 2011 | https://conductscience.org/library/papers/21905107 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42277171 | A tri-target in silico analysis of Testolift: a nutraceutical formulation targeting aromatase, myostatin, and prolyl hydroxylase-2 in testosterone regulation and muscle performance. | Sci Rep | 2026 | https://conductscience.org/library/papers/42277171 | PubMed |
| 41065364 | Molecular screening of natural compounds targeting KRAS(G12C): a multi-parametric strategy against acute lymphoblastic leukemia. | J Enzyme Inhib Med Chem | 2025 | https://conductscience.org/library/papers/41065364 | PubMed |
| 40872535 | Repurposing Nirmatrelvir for Hepatocellular Carcinoma: Network Pharmacology and Molecular Dynamics Simulations Identify HDAC3 as a Key Molecular Target. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40872535 | PubMed |
| 40552160 | Structure-based molecular screening and dynamic simulation of phytocompounds targeting VEGFR-2: a novel therapeutic approach for papillary thyroid carcinoma. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40552160 | PubMed |
| 40430547 | Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40430547 | PubMed |
| 40122680 | Molecular pathways in cardiovascular disease under hypoxia: Mechanisms, biomarkers, and therapeutic targets. | J Biomed Res | 2025 | https://conductscience.org/library/papers/40122680 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGLN1 | 54583 | PubTator's text mining | https://conductscience.org/library/genes/54583 | NCBI Gene |
| EPO | 2056 | PubTator's text mining | https://conductscience.org/library/genes/2056 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39593151
GET https://conductscience.org/api/papers/v1/39593151/references?page=2